Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration

Table 1

Demographic parameters.

	AMD	DR		Control
N	19	17	ns (FT)	22
Sex (f/m)	11/8	6/11	ns (FT)	10/12	>0.05 (CS)
Age (median/mean ± SD)	78/75 ± 10.6	63/63 ± 14.3	0.0072	77/75 ± 7.6	(KW); (C vs. DR); (C vs. AMD); (AMD vs. DR)
Baseline IGF-1 (median/mean ± SD (pg/ml))	35/37 ± 12.8	57/65 ± 32.1		49/54 ± 18.5	(KW); (C vs. DR); (C vs. AMD); (AMD vs. DR)
IQR	24–51	37–99		43–61
Baseline VEGF-A (median/mean ± SD (pg/ml))	43/42 ± 16	53/75 ± 57.01		61/87 ± 78.8	(KW); (C vs. DR); (C vs. AMD); (AMD vs. DR)
IQR	30–57	35–117		38–112

AMD: age-related macular degeneration; DR: diabetic retinopathy; C: control; VEGF-A: vascular endothelial growth factor-A; IGF-1: insulin-like growth factor-1; FT: Fisher’s exact test; KW: Kruskal–Wallis test; CS: chi-square test; ns: not significant; n: number; SD: standard deviation.